Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $183.2652W HIGH $382.54
Volume
60.86 K
Value Traded
49.92 M
Short % Float
13.38%
Days to Cover
11.2
-2.62%Week
-7.48%1 Month
-11.36%3 Month
+14.34%6 Month
+337.03%5 Year
+2,751.9%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.26 B
EPS (TTM)
8.16
P/E Ratio
38.23
Ent. Value
8.39 B
Total Shares
29.59 M
Float Shares
25.97 M
Insiders
12.26%
Institutions
99.45%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
KRYS Catalyst Timeline
Dated clinical, regulatory and corporate events for Krystal Biotech, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Krystal Biotech, Inc.
757Total events
27Upcoming
130Tier-1 (high impact)
2017 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutKB113Clinical Data
Positive clinical update: >80% of assessed BCC lesions regressed in three Gorlin syndrome patients
Basal cell carcinoma in Gorlin syndromesource ↗
●Poster PresentationKB113Presentation
Poster of Gorlin Syndrome Pilot Study results presented at PeDRA Annual Conference
basal cell carcinoma in patients with Gorlin syndromesource ↗
▲Additional DataKB113Clinical Data
KB113 shows >80% BCC lesion regression in three Gorlin syndrome patients
basal cell carcinoma in patients with Gorlin syndromesource ↗
▲Other Regulator MilestoneVYJUVEKApprovedEx-US Regulatory
VYJUVEK received Prix Galien UK Award for Best Product for Orphan Disease
Dystrophic Epidermolysis Bullosasource ↗
◆Poster PresentationKB707Presentation
Poster presentation on KB707 with pembrolizumab in NSCLC at ASCO 2026
advanced non-small cell lung cancersource ↗
◆Oral PresentationKB407FiledPresentation
Oral presentation of interim results of CORAL-1 trial of KB407 for cystic fibrosis at ATS 2026
cystic fibrosissource ↗
▲MHRA MilestoneVYJUVEKApprovedEx-US Regulatory
MHRA granted marketing authorization for VYJUVEK in the UK
dystrophic epidermolysis bullosasource ↗
▲Orphan Drug DesignationVYJUVEKApprovedDesignation
VYJUVEK fulfilled UK Orphan Designation criteria and added to Orphan Register
dystrophic epidermolysis bullosasource ↗
◆Oral PresentationPresentation
Krystal Biotech to present at BofA Securities 2026 Health Care Conference
◆Poster PresentationKB409Presentation
Poster presentation on KB409 and KB410 for PCD at ASGCT 2026
primary ciliary dyskinesiasource ↗
◆Poster PresentationKB410Presentation
Poster presentation on KB409 and KB410 for PCD at ASGCT 2026
primary ciliary dyskinesiasource ↗
▲Enrollment CompleteKB803Trial
Enrollment complete in KB803 registrational study (IOLITE)
corneal abrasions in DEB patientssource ↗
●Trial InitiationKB407FiledTrial
Initiation of open-label repeat-dose KB407 study in CF patients
cystic fibrosis (CF)source ↗
●Trial InitiationKB111Trial
Initiation of HALITE-1 open-label study for KB111 expected later this month (May 2026)
Hailey-Hailey disease (HHD)source ↗
▲Other Regulator MilestoneVYJUVEKApprovedEx-US Regulatory
VYJUVEK approved by UK MHRA in May 2026
Dystrophic Epidermolysis Bullosasource ↗
●Oral PresentationPresentation
Presented preclinical data at ASGCT 2026 Annual Meeting in May
Primary ciliary dyskinesiasource ↗
▲Oral PresentationKB707Presentation
Presented interim clinical results at ASCO 2026 Annual Meeting in May
Non-small cell lung cancersource ↗
▲FDA ApprovalVYJUVEKApprovedFDA Decision
VYJUVEK approved by UK MHRA in May
Dystrophic Epidermolysis Bullosasource ↗
●Trial InitiationKB407FiledTrial
Anticipating enrollment start in CORAL-3 in 2Q 2026
cystic fibrosissource ↗
◆Timing GuidanceVYJUVEKApprovedPresentation
Potential commercial launch in Italy in 2H 2026
dystrophic epidermolysis bullosa (DEB)source ↗
◆Trial InitiationKB111Trial
Expected initiation of registrational study for KB111 in HHD
Hailey-Hailey disease (HHD)source ↗
◆Product LaunchVYJUVEKApprovedPost-Market
Potential launch of VYJUVEK in Italy in 2H 2026
dystrophic epidermolysis bullosa (DEB)source ↗
▲Platform ValidationKB407FiledPreclinical
FDA grants platform technology designation for KB407 (CF)
cystic fibrosis (CF)source ↗
▲Platform ValidationKB111Preclinical
FDA grants platform technology designation for KB111 (HHD)
Hailey-Hailey disease (HHD)source ↗
▲Enrollment CompleteKB407FiledTrial
Enrollment completion expected for KB407 open-label study in 2Q 2026
cystic fibrosis (CF)source ↗
▲Enrollment CompleteKB803Trial
IOLITE study fully enrolled in April
Corneal abrasions in DEB patientssource ↗
◆Oral PresentationPresentation
Krystal Biotech to present at TD Cowen 46th Annual Health Care Conference
▲RMATKB707Designation
FDA granted RMAT designation to KB707 for advanced NSCLC
advanced non-small cell lung cancer (NSCLC)source ↗
▲Fast Track DesignationKB111Designation
FDA granted Fast Track designation to KB111 for HHD
Hailey-Hailey disease (HHD)source ↗
▲RMATKB707Designation
FDA granted RMAT designation to KB707 for NSCLC
advanced or metastatic non-small cell lung cancersource ↗
◆Quarterly UpdateCorporate
Full financial results for Q4 and full year 2025 to be reported in February 2026
◆Timing GuidanceKB801Presentation
Detailed update on KB801 registrational study design when reporting 2025 financial results
neurotrophic keratitissource ↗
▲RMATKB707Designation
FDA granted RMAT designation to KB707 for NSCLC
advanced or metastatic non-small cell lung cancer (NSCLC)source ↗
▲Partnership / LicenseVYJUVEKApprovedCorporate
Executed agreement with regional specialty distributor for VYJUVEK in Israel
dystrophic epidermolysis bullosa (DEB)source ↗
▲Enrollment UpdateKB801Trial
Increased enrollment target for KB801 registrational study from 27 to 60 patients
neurotrophic keratitissource ↗
◆Interim AnalysisKB407FiledTrial
Interim clinical update from highest dose cohort of Phase 1 CORAL-1 study
cystic fibrosissource ↗
●Oral PresentationKB407FiledPresentation
Investor conference call and webcast to discuss data update and timelines
cystic fibrosissource ↗
◆FDA Feedback ReceivedKB407FiledFDA Meeting
Expected alignment on CORAL-3 study design with FDA in 1Q 2026
cystic fibrosissource ↗
◆Trial InitiationKB407FiledTrial
Expected start of enrollment in CORAL-3 for KB407 in CF
cystic fibrosis (CF)source ↗
▲Fast Track DesignationKB111Designation
FDA granted Fast Track Designation to KB111 for HHD
Hailey-Hailey disease (HHD)source ↗
▲Topline ReadoutKB407FiledClinical Data
Positive clinical update from highest dose cohort of CORAL-1 for KB407 in CF
cystic fibrosis (CF)source ↗
◆Enrollment CompleteKB803Trial
Expected completion of enrollment in IOLITE for KB803
corneal abrasions in DEB patientssource ↗
▲Trial InitiationKB111Trial
HALITE-1 started enrolling and dosing patients
Hailey-Hailey diseasesource ↗
◆Oral PresentationPresentation
Krystal Biotech to present at 8th Annual Evercore Healthcare Conference
●FDA Filing AcceptedKB407FiledRegulatory Filing
CORAL-3 registrational study design submitted to FDA in late December 2025
cystic fibrosissource ↗
Past FDA Catalysts and PDUFA Decisions
How KRYS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | KB408 | Phase 1 interim results | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
8
Drugs Scored
rNPV / MCap
Top Drug
Top 11%
Small Cap(rank 73 of 657)
Percentile Rank
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q))
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VYJUVEK |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KB407 Monoclonal antibodyNCT05504837 | Cystic Fibrosis | Phase 1 | RECRUITING | 20 | Mar 1, 2027 | ||||||
| KB304 Monoclonal antibodyNCT06724900 | Wrinkles in Decolletage | Phase 1 | ACTIVE NOT_RECRUITING | 19 | Aug 1, 2025 | ||||||
| KB707 Monoclonal antibodyNCT06228326 | Lung Cancer, Non-small Cell | Phase 1 | RECRUITING | 250 | Jul 1, 2028 | ||||||
| KB707 Monoclonal antibodyNCT05970497 | Cancer | Phase 1 | RECRUITING | 240 | Jul 1, 2027 | ||||||
| KB408 Small moleculeNCT06049082 | Alpha 1-Antitrypsin Deficiency | Phase 1 | RECRUITING | 15 | Dec 1, 2026 | ||||||
| KB301 Monoclonal antibodyNCT04540900 | Skin Roughness | Phase 1 | ACTIVE NOT_RECRUITING | 85 | May 31, 2029 | ||||||
| KB111 Monoclonal antibodyNCT07717346 | Hailey Hailey Disease | Phase 1 | RECRUITING | 7 | Dec 1, 2026 | ||||||
| KB801 Monoclonal antibodyNCT06999733 | Neurotrophic Keratitis | Phase 1 | RECRUITING | 60 | Dec 1, 2027 | ||||||
| KB803 Monoclonal antibodyNCT07016750 | Dystrophic Epidermolysis Bullosa | Phase 3 | RECRUITING | 16 | Dec 1, 2026 | ||||||
| beremagene geperpavec Gene therapyMarketedNCT03536143 | Dystrophic Epidermolysis Bullosa | Phase 3 | COMPLETED | 90 | Nov 1, 2019 |
Clinical Trial Results
Readouts, endpoints and source filings for every KRYS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| KB113 | Basal Cell Carcinoma in Gorlin Syndrome | 2026-10-15 | over 80% of assessed basal cell carcinoma lesions regressedRead More | Krystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin SyndromeRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Krishnan SumaDirector, Officer (President, R&D), 10% Owner | Sell | -520 1,326,625 held | $354.54 | 09/04/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in KRYS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 9.6 % (31.5 %) | 1.07 B | 2.89 M |
KRYS Institutional Ownership Trends
KRYS Short Interest
Shares sold short, counted twice a month.
13.38%
Short % of Float
of tradable shares sold short
3.5M
Shares Sold Short
+9.9% vs prior count
11.2 Very high
Days to Cover
trading days of normal volume to buy every short share back
310.5K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How KRYS ranks across every disease it competes in
Competitive Position is a premium feature
See how KRYS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialKRYS News
KRYSKrystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026
Krystal Biotech, Inc. will report its third quarter 2026 financial results on November 2, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 am ET to discuss these results and provide a business update. The event will be accessible to investors and the public via a live webcast.
Read more →KRYSKrystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin Syndrome
Krystal Biotech announced promising clinical results for KB113, an immunotherapy for Gorlin syndrome patients. In a pilot study, over 80% of basal cell carcinoma lesions regressed, including significant responses in non-injected lesions. The treatment was well tolerated, with only mild adverse effects reported. Results will be presented at the upcoming PeDRA Annual Conference.
Read more →KRYSKrystal Biotech to Present at 2026 Cantor Global Healthcare Conference
Krystal Biotech, Inc. will present at the 2026 Cantor Global Healthcare Conference on September 10, 2026. The event will feature a fireside chat with management and investor meetings throughout the day. A webcast of the presentation will be available on the company's website.
Read more →KRYS▼ -8.4%on this news
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results
Krystal Biotech reported strong financial results for Q2 2026, with VYJUVEK generating $119.2 million in revenue, marking a 24% increase year-over-year. The company is advancing its pipeline with multiple clinical data readouts expected in the second half of 2026 and is on track for launches in Spain and Italy. Krystal's balance sheet remains strong, with $1.1 billion in cash and investments.
Read more →KRYSKrystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026
Krystal Biotech, Inc. announced it will report its second quarter 2026 financial results on August 3, 2026. A conference call and webcast will follow at 8:30 am ET to discuss the results and provide a business update. Investors can access the live event and a subsequent replay on the company's website.
Read more →KRYSKrystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech announced that its gene therapy, VYJUVEK, received marketing authorization from the UK's MHRA for treating dystrophic epidermolysis bullosa (DEB) from birth. This marks VYJUVEK as the first genetic medicine approved in the UK for this condition. The therapy aims to address the root cause of DEB by delivering functional copies of the COL7A1 gene, ensuring effective wound healing. Following approvals in the US, EU, and Japan, the company looks to ensure broad access for patients in the UK.
Read more →KRYSKrystal Biotech to Present at BofA Securities 2026 Health Care Conference
Krystal Biotech, Inc. will present at the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. CEO Krish S. Krishnan will participate in a fireside chat and host investor meetings. The event underscores the company's commitment to advancing genetic medicines, including its first product, VYJUVEK®, approved for dystrophic epidermolysis bullosa.
Read more →KRYS▲ +7.9%on this newsshared move
Krystal Biotech Announces First Quarter 2026 Financial and Operating Results
Krystal Biotech reported strong financial results for Q1 2026, with VYJUVEK generating $116.4 million in revenue, a 32% increase from the previous year. The company has completed enrollment in its registrational study for KB803 and is on track for data readouts in 2026. Additionally, the FDA granted platform technology designation for KB407 and KB111, enhancing regulatory advantages for these products. The company maintains a robust cash position of $1.0 billion.
Read more →KRYSKrystal Biotech to Present at Upcoming Scientific Conferences
Krystal Biotech, Inc. will present at several upcoming scientific conferences in May and June 2026. Key presentations include evaluations of gene therapy vectors for primary ciliary dyskinesia and interim results from a cystic fibrosis trial. The company's innovative approaches to genetic medicine are showcased at these events.
Read more →KRYSKrystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026
Krystal Biotech, Inc. will report its first quarter 2026 financial results on May 4, 2026. The announcement includes a conference call and webcast at 8:30 am ET to discuss the results and provide a business update. Investors can access the live webcast online, with a replay available for 30 days.
Read more →KRYSKrystal Biotech to Present at TD Cowen 46th Annual Health Care Conference
Krystal Biotech, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. The company will participate in a fireside chat and hold investor meetings throughout the day. A webcast of the presentation will be available on their website.
Read more →KRYSKrystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Krystal Biotech reported fourth quarter VYJUVEK revenue of $107.1 million and full year net product revenue of $389.1 million. The company ended the quarter with $955.9 million in cash and investments. The FDA granted Regenerative Medicine Advanced Therapy designation to KB707 for advanced non-small cell lung cancer. Fast Track Designation was also awarded to KB111 for the treatment of Hailey-Hailey disease.
Read more →KRYSKrystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Krystal Biotech, Inc. will report its fourth quarter and full year 2025 financial results on February 17, 2026. The company will also host a conference call and webcast to discuss these results and provide a business update. Investors can access the live webcast and a replay will be available for 30 days on the company's website.
Read more →KRYSKrystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
Krystal Biotech has received RMAT designation from the FDA for KB707, an immunotherapy aimed at treating advanced or metastatic non-small cell lung cancer (NSCLC). This designation highlights the urgent need for new therapies in NSCLC and is supported by promising early clinical data from the ongoing KYANITE-1 study. The RMAT designation will facilitate accelerated development and potential approval processes for KB707.
Read more →KRYSKrystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech, Inc. has announced preliminary unaudited financial results for 2025, projecting net product revenue for VYJUVEK between $106 million and $107 million for the fourth quarter. The company outlined its strategic vision for growth in rare diseases, emphasizing a strong clinical pipeline and significant cash reserves of approximately $955 million. With plans to launch additional therapies and expand its reach, Krystal aims to have at least four marketed rare disease medicines by 2030. The announcement coincides with their upcoming presentation at the 44th Annual J.P. Morgan Healthcare Conference.
Read more →KRYS▲ +5%on this news· ran to +17% by day 3shared move
Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis
Krystal Biotech announced positive interim results from its Phase 1 CORAL-1 study of KB407, confirming successful delivery of wild-type CFTR protein in patients with cystic fibrosis. The study demonstrated high transduction rates across diverse patient backgrounds. The company plans to initiate the registrational CORAL-3 study in 2026, aiming to evaluate repeat dosing of KB407.
Read more →KRYSKrystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis
Krystal Biotech, Inc. announced it will hold an investor conference call on January 8, 2026, to provide an interim update from its Phase 1 CORAL-1 study evaluating KB407 for cystic fibrosis. The update will focus on molecular assessments related to KB407 transduction and CFTR protein expression in patients receiving the highest dose. This follows the company's ongoing commitment to develop genetic medicines for unmet medical needs.
Read more →KRYSKrystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference
Krystal Biotech, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. CEO Krish S. Krishnan will lead the presentation at 10:30 am ET and host investor meetings throughout the day. The event highlights the company's commitment to advancing genetic medicines for unmet medical needs.
Read more →KRYSKrystal Biotech to Present at 8th Annual Evercore Healthcare Conference
Krystal Biotech, Inc. will present at the 8th Annual Evercore Healthcare Conference on December 3, 2025, in Miami. CEO Krish S. Krishnan will participate in a fireside chat and host investor meetings. A webcast of the presentation will be available on the company's website, promoting transparency with investors.
Read more →KRYSKrystal Biotech Announces Third Quarter 2025 Financial and Operating Results
Krystal Biotech reported $97.8 million in third quarter revenue for VYJUVEK, bringing total U.S. sales to $623.2 million since launch. The company ended the quarter with $864.2 million in cash and investments. VYJUVEK launched in Germany, France, and Japan during the period. The FDA also granted a platform technology designation for the KB801 program.
Read more →About Krystal Biotech, Inc.
Headquarters2100 WHARTON STREET, PITTSBURGH, PA, 15203
BIOPHARMAWATCH ELITE PLUS
Trade the next KRYS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime